Table 1 Characteristics of study populations used in this study
Characteristic | Group | |
|---|---|---|
Nodule-positive | Endemic controls | |
No. of subjects | 99 | 51 |
Age, median (min-max) | 47 (21–85) | 35 (18–81) |
Gender, n (%) | ||
 Male | 53 (54) | 26 (51) |
 Female | 46 (46) | 25 (49) |
No. of nodules, median (min-max) | 1 (1–5) | 0 |
mf status, n (%) | ||
 0 mf/mg | 89 (90) | 51 (100) |
 0–5 mf/mg | 9 (9) | 0 (0) |
 5–10 mf/mg | 1 (1) | 0 (0) |
No. of IVM rounds, median (min-max) | 2 (0–10) | 0 (0–1) |
Time since last treatment | ||
 Not treated | 16 (16) | 34 (67) |
  < 20 months | 68 (69) | 5 (10) |
  > 20 months | 15 (15) | 12 (24) |
Ov16 status, n (%) | ||
 Positive | 68 (69) | 26 (51) |
 Negative | 31 (31) | 25 (49) |